About GENSCRIPT BIO Company

GenScript Biotech Corporation (the "Company," together with its subsidiaries, the "Group" or "GenScript") is a widely recognized biotechnology company. Leveraging our proprietary gene synthesis technology, as well as other technologies and expertise in life sciences research and applications, we have successfully established several key platforms: (i) the GenScript-branded life sciences services and products platform ("GenScript"), which provides one-stop solutions to the global scientific community; (ii) Probio Technology Limited ("Probio Cayman" or "Probio"), a contract development and manufacturing organization (CDMO) platform for biologics; and (iii) Bestzyme Biotech Corporation ("Bestzyme"), an industrial synthetic products platform. During the six-month period ended June 30, 2025 (the "Reporting Period"), these internally developed platforms delivered robust growth across the entire value chain, from R&D through commercial delivery. The Group holds a significant investment in Legend Biotech Corporation ("Legend," together with its subsidiaries, the "Legend Group"), a globally leading biotechnology company dedicated to the development of cell therapies. The Group's operations span more than 100 countries and regions worldwide, with legal entities in Mainland China, the United States, Hong Kong, Japan, Singapore, the Netherlands, the United Kingdom, South Korea, Spain, Australia, and Macau. As of June 30, 2025, our professional team comprised approximately 5,769 members. GenScript offers gene synthesis, protein production, peptide synthesis, oligonucleotide synthesis, antibody development, as well as life sciences equipment and consumables. We serve pharmaceutical, biotechnology, and academic researchers in over 100 countries, supporting early discovery and innovation through high-quality, reliable, and scalable solutions. In 2025, we accelerated our marketing transformation by embracing a data-driven, digitally empowered, and customer-centric approach. This repositioning has already yielded tangible results in terms of growth, engagement, and impact. Probio is a subsidiary of the Group. As a leading CDMO, Probio empowers global biologics innovators by delivering seamless end-to-end solutions. Our integrated platform combines discovery, development, and manufacturing services, streamlining the development process, reducing timelines, and increasing the success rate of biologics projects. By accelerating the development and production of life-changing biologic therapies, we are committed to improving the lives of patients worldwide and building a healthier future. Bestzyme is a subsidiary of the Group engaged in industrial synthetic biology. Bestzyme applies our advanced protein engineering technologies to develop products for the feed, food, grain-processing, and home-care industries. We believe that synthetic biology presents new technological and commercial opportunities for us. Legend is a significant associate of the Group, specializing in the discovery and development of novel cell therapies for cancer and other indications. Legend's lead candidate, cilta-cel, is a chimeric antigen receptor T-cell (CAR-T) therapy co-developed with Janssen Biotech, Inc., indicated for the treatment of multiple myeloma (MM).